Renzapride
- Generic Name
- Renzapride
- Drug Type
- Small Molecule
- Chemical Formula
- C16H22ClN3O2
- CAS Number
- 112727-80-7
- Unique Ingredient Identifier
- 9073C0W4E9
Overview
Renzapride is currently in Phase III clinical development in the United States for the treatment of constipation-predominant irritable bowel syndrome (IBS-C). It has been suggested that renzapride is effective in the treatment of irritable bowel syndrome with alternating stool pattern. It is being developed by Alizyme of the UK.
Background
Renzapride is currently in Phase III clinical development in the United States for the treatment of constipation-predominant irritable bowel syndrome (IBS-C). It has been suggested that renzapride is effective in the treatment of irritable bowel syndrome with alternating stool pattern. It is being developed by Alizyme of the UK.
Indication
For the treatment of constipation-predominant irritable bowel syndrome (IBS-C).
Associated Conditions
No associated conditions information available.
Clinical Trials
FDA Approved Products
Singapore Approved Products
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.